Tasly Pharmaceutical Group Co Ltd Capital Reinvestment Ratio
Tasly Pharmaceutical Group Co Ltd capital reinvestment ratio. Tasly Pharmaceutical Group Co Ltd (600535) has a Capital Reinvestment Ratio of 0.21x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥552.13 Million) in capital expenditures (CN¥117.78 Million). Check Tasly Pharmaceutical Group Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Tasly Pharmaceutical Group Co Ltd (2001–2025)
Capital reinvestment ratio of Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. This chart tracks Tasly Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 24 annual periods. Also explore Tasly Pharmaceutical Group Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Tasly Pharmaceutical Group Co Ltd Capital Reinvestment Ratio by Year (2001–2025)
Tasly Pharmaceutical Group Co Ltd capital reinvestment ratio by year from 2001 to 2025. For the full cash flow conversion analysis, see Tasly Pharmaceutical Group Co Ltd cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.27x | CN¥1.42 Billion | CN¥381.26 Million | ▼ -4.6% |
| 2024 | 0.28x | CN¥2.01 Billion | CN¥564.94 Million | ▲ +8.0% |
| 2023 | 0.26x | CN¥2.58 Billion | CN¥668.82 Million | ▲ +47.1% |
| 2022 | 0.18x | CN¥2.29 Billion | CN¥403.45 Million | ▼ -13.5% |
| 2021 | 0.20x | CN¥2.80 Billion | CN¥571.73 Million | ▼ -10.6% |
| 2020 | 0.23x | CN¥1.79 Billion | CN¥408.81 Million | ▼ -47.5% |
| 2019 | 0.43x | CN¥1.68 Billion | CN¥730.78 Million | ▼ -16.7% |
| 2018 | 0.52x | CN¥1.49 Billion | CN¥780.10 Million | ▲ +14.8% |
| 2016 | 0.45x | CN¥1.15 Billion | CN¥524.68 Million | ▼ -79.0% |
| 2015 | 2.17x | CN¥340.00 Million | CN¥737.84 Million | ▲ +77.3% |
| 2014 | 1.22x | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥83.77 Million | CN¥119.35 Million | — |